CBT Isolate (Cannabicitran) is a rare minor cannabinoid naturally present in the hemp plant, typically occurring in very small concentrations. Due to its scarcity, CBT Isolate has gained growing interest for specialised cannabinoid formulations where functional performance is prioritised. 

One of the most notable properties of CBT is its use as an anti-crystallisation agent. CBT can help cannabinoids such as CBD remain in a stable, non-crystalline form, reducing the tendency of compounds to recrystallise during processing or storage. This makes CBT a valuable ingredient in formulations where texture, clarity, and physical stability are critical. 

Research also suggests that CBT may exhibit functional similarities to CBD, particularly in its interaction with other cannabinoids. Preliminary studies indicate that CBT may help moderate the psychoactive effects of THC, contributing to more balanced cannabinoid profiles. While research into CBT is still emerging, these characteristics have positioned it as an innovative minor cannabinoid for advanced product development. 

As interest in rare cannabinoids continues to expand, CBT is increasingly explored for applications in formulation stabilisation, cannabinoid synergy, and next-generation hemp-derived products.